Lulirif Cream contains Luliconazole 1% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial dermatophytic infections such as tinea corporis, tinea cruris, and tinea pedis. Luliconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The cream formulation allows for targeted application to affected skin areas, promoting rapid symptom relief including reduction of itching, redness, and scaling. Lulirif Cream is typically applied once daily to the clean, dry affected area for a duration recommended by a healthcare professional, usually ranging from 1 to 2 weeks depending on the severity and type of infection. It is well tolerated with minimal systemic absorption, reducing the risk of systemic side effects. Common adverse reactions may include mild local irritation, burning sensation, or erythema at the application site. Lulirif Cream should be used with caution in patients with known hypersensitivity to Luliconazole or other imidazole antifungals. It is contraindicated in mucosal infections and should not be applied to open wounds. Proper adherence to treatment duration is essential to prevent recurrence and resistance.